Hengrui Medicine: Net profit of 349 million yuan in 2025, actively advancing the research and development of multiple candidate drugs.

LightningPacketLoss · 2026-03-31T10:39:51+00:00

Hepalink's 2025 annual report shows the company’s operating revenue reached 5.48 billion yuan, a year-on-year increase of 3.8%; net profit attributable to the parent was 349 million yuan, a decrease of 46% year-on-year. The heparin industry chain and CDMO business performed steadily, with smooth progress in innovative drug research and development, especially demonstrating excellent performance in global market expansion. Overall business development remains stable.

LightningPacketLoss

2026-03-31 10:39:51

Abstract generation in progress

Recently, Haispuirui released its 2025 annual report. The company’s operating revenue was 5.48 billion yuan, up 3.8% year over year; net profit attributable to shareholders was 349 million yuan, down 46% year over year; non-recurring profit net profit attributable to shareholders was 421 million yuan, up 66.1% year over year; net operating cash flow was 1.713 billion yuan, down 21.9% year over year; and EPS (fully diluted) was 0.2382 yuan.

In its 2025 annual report, the company mentioned that its main operating businesses include the heparin industry chain, biologics macromolecule CDMO, and investment and development of innovative drugs. During the reporting period, the heparin industry chain business achieved sales revenue of 4.309 billion yuan, up 6.24% year over year. Global formulation sales achieved double-digit growth, with sales revenue reaching 3.509 billion yuan, up 17.52% year over year. In addition, the CDMO business recorded sales revenue of 1.033 billion yuan, remaining stable.

In the area of innovative drugs, the company is actively advancing R&D for multiple candidate drugs, including the oncology candidate drug H1710. The drug has received approval for clinical trials and is currently undergoing clinical research. At the same time, the report also emphasized the company’s expansion strategy in global markets, particularly its strong performance in Europe and overseas markets outside the US and Europe, with sales growing significantly. Overall, the company has maintained stable business development and an increase in market share despite facing challenges from the external environment.

(Haispuirui announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.